Elobixibat is under clinical development by Albireo Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Elobixibat’s likelihood of approval (LoA) and phase transition for Non-Alcoholic Steatohepatitis (NASH) took place on 22 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Elobixibat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Elobixibat overview

Elobixibat (AJG533, A3309, Goofice) is a bile acid transport inhibitor. It is formulated as tablets for oral route of administration. Goofice is indicated for the treatment of chronic constipation. It is under development for the treatment of chronic idiopathic constipation (CIC) and constipation predominant irritable bowel syndrome (IBS-C) in Japan. It is administered orally. The drug candidate acts by targeting ileal bile acid transporter (IBAT).

Elobixibat is under development for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). It is administered by oral route as a tablet. Elobixibat was also under development for the treatment of dyslipidemia and chronic idiopathic constipation (CIC) and constipation predominant irritable bowel syndrome (IBS-C).

Albireo Pharma overview

Albireo Pharma (Albireo), formerly Biodel, It focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.

Quick View Elobixibat LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Elobixibat
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.